Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 80 publications.

Hoerger TJ, Zhang P, Segel JE, Gregg EW, Venkat Narayan KM, Hicks KA. Improvements in risk factor control among persons with diabetes in the United States: evidence and implications for remaining life expectancy. Diabetes Res Clin Pract. 2009 Dec 1;86(3):225-32.

Debanjali M, Hodgkins P, Yen L, Solomon D, Davis KL, Cohen R. Adherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis: impact on all-cause healthcare costs. Inflamm Bowel Dis. 2009 Dec 1;15(12):S32.

Candrilli SD, O'Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Poster presented at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition; December 5, 2009. New Orleans, LA. [abstract] Blood. 2009 Nov 20; 114(22):2483. doi: 10.1182/blood.V114.22.2483.2483

Wolowacz S. The United Kingdom's national institute for health and clinical excellence: new developments. Poster presented at the 2009 ISPOR 12th Annual European Congress; November 19, 2009.

Zarkin GA, Cowell AJ, Dunlap LJ, Hicks KA, Keyes VS, Mills MJ. Benefits and costs of alternative substance abuse treatment programs for individuals in state prisons: results from a lifetime simulation model. Presented at the American Society of Criminology Annual Meeting; November 2009. Previously presented at the Addiction Health Services Research Annual conference.

Cowell AJ, Zarkin GA, Dunlap LJ, Hicks KA, Keyes VS, Mills MJ. Findings on drug use, crime, arrests, and other model outcomes from a simulation model of prison-based substance abuse treatment. Presented at the American Society of Criminology Annual Meeting; November 2009.

Talbird SE, Brogan AJ, Winiarski AP. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S. Am J Prev Med. 2009 Nov 1;37(5):381-8.

Smets E, Stoll M, Hill A, Soorapanth S, Donatz V, Brogan AJ. Comparative cost-efficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in Germany. Poster presented at the 12th European AIDS Conference/EACS; November 2009.

Jackel J, Davis KL, Patel A. Stroke in the long-term care setting: patient characteristics and medication treatment. Poster presented at the Annual Meeting of the American Society of Consultant Pharmacists; November 2009.

Jackel J, Davis KL, Patel A. TIA in the long-term care setting: patient characteristics and medication treatment. Poster presented at the Annual Meeting of the American Society of Consultant Pharmacists; November 2009.

Hicks KA, Zarkin GA, Dunlap LJ, Cowell AJ, Mills MJ, Keyes VS. A dynamic model for estimating the costs and benefits on prison-based substance abuse treatment. Poster presented at the American Society of Criminology Annual Meeting; November 2009.

Wolowacz S, Jhaveri M, Tangirala K. Cost-utility model to evaluate adjuvant chemotherapy for early breast cancer in the United States. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009.

Mehta HB, Parikh RC, Sujit SS. Cost-effectiveness analysis of anti-obesity treatments: orlistat, sibutramine and behavioral therapy. Poster presented at the 31st Society of Medical Decision Making Conference; October 19, 2009. Los Angeles, CA.

Zarkin GA, Cowell AJ, Hicks KA, Dunlap LJ, Belenko S, Mills MJ. Benefits and costs of alternative substance abuse treatment programs for individuals in state prisons: results from a lifetime simulation model. Presented at the Addiction Health Services Research Annual conference; October 2009.

Wolowacz S, Samuel M, Brennan VK, Jasso-Mosqueda J, van Gelder I. The cost of illness of atrial fibrillation: a systematic review. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A325.

Mitra D, Hodgkins P, Yen L, Solomon D, Davis KL, Cohen RD. The impact of oral 5- ASA adherence on all-cause health care costs among ulcerative colitis patients. Poster presented at the Annual Scientific Meeting and Postgraduate Course of the American College of Gastroenterology; October 2009.

Mitra D, Davis KL, Hodgkins P, Yen L, Solomon D, Cohen RD. Assessing the relationship between adherence and health care costs: evidence from a managed care population with ulcerative colitis. Poster presented at the 31st Annual Meeting of the Society for Medical Decision Making; October 2009.

Kauf T, Davis KL, Earnshaw S, Davis EA, Watson ME. Spillover adherence effects of fixed-dose combination HIV therapy. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A430.

Candrilli SD, Davis KL, Balkrishnan R, O'Brien S. Changes in rates of sickle cell disease-related inpatient stays and associated resource use among African Americans in the United States following approval of hydroxyurea. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France.

Mauskopf J, Graham JB, Bae J, Gaich C. Impact of including prasugrel on the formulary for patients who undergo percutaneous coronary intervention for acute coronary syndrome. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A322.

Earnshaw S, McDade CL, Black L, Kattan M. Cost-effectiveness of chemoprevention with dutasteride based on results from the REDUCE clinical trial. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A371.

Smets E, Soorapanth S, Brogan AJ, Mrus J. Cost-efficacy analysis of darunavir/r vs. lopinavir/r as a first-line HIV treatment in the United States. Poster presented at the 47th Annual Meeting of the Infectious Diseases Society of America; October 2009.

Papanicolaou S, Kontodimas S, Syriopoulou E, Tsolia M, Theodoridou M, Kremastinou J, Tzanakaki G, Strutton D, Hwang S, Earnshaw SR. Clinical and economic benefits of national immunization with the 13-valent compared to 7- and 10-valent pneumococcal conjugate vaccines in Greece. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A423-4.

Mladsi D, de Cambra S, Gilabert-Perramon A, Faulkner EC. Orphan drug funding: a model for personalized medicine? Presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France.

Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, Papadopoulos G. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high risk patients. Am J Health Syst Pharm. 2009 Oct;66(19):1711-7. doi: 10.2146/ajhp080325.

Farkouh R, Wilson M, Tarrants ML, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline compared with other first-line treatment options for early parkinson's disease in the United States. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A369.

Jackel J, Davis KL, Candrilli SD. Trends in rates of pediatric bipolar disorder-related hospitalizations and related resource use in the United States. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France.

Bapat BS, Bell TJ, Candrilli SD. Estimates of the indirect burden of invasive meningococcal disease: insight from public health officials. Poster presented at the 47th Annual Meeting of the Infectious Diseases Society of America; October 2009.

Knoll S, Jochum D, Talbird SE. Cost-utility analysis of pneumococcal conjugate vaccines in Germany. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A429.

Ismaila A, Pereira J, Robson R, Talbird SE, Standaert B, Rawson N. Budget-impact analysis of adding the new 10-valent pneumococcal conjugate vaccination (PHiD-CV) to routine infant vaccination in Canada. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A418.

Whillans F, Kwan H, Strutton DR, Earnshaw SR, Farkouh RA. Cost-effectiveness of 13-valent and 10-valent pneumococcal conjugate vaccination relative to 7-valent pneumococcal conjugate vaccination in Canada. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A425.

Gonzalez-Rojas N, Vieta A, Monreal M, Wolowacz SE. Economic analysis of dabigatran etexilate for the primary prevention of venous thromboembolism following total hip or knee replacement in Spain. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 24, 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A440.

Candrilli SD, Davis KL, Iyer S. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy. J Pain Palliat Care Pharmacother. 2009 Sep 1;23(3):231-41.

Candrilli SD, Balkrishnan R, O'Brien SH. Effect of injury severity on the incidence and utilization-related outcomes of venous thromboembolism in pediatric trauma inpatients. Pediatr Crit Care Med. 2009 Sep 1;10(5):554-7.

Berria R, Rosenstock J, Silberman C, Davis KL, Horton ES. Weight loss and associated changes in glycaemic control and cardiovascular biomarkers in patients with type 2 diabetes mellitus receiving incretin therapies in a large cohort database. Poster presented at the 44th General Assembly of the European Association for the Study of Diabetes; September 2009. [abstract] Diabetologia. 2009 Sep; 52(Suppl. 1, Abst.755):S297.

Lasry A, Sansom S, Hicks KA, Uzunangelov VJ. A model for allocating HIV prevention resources in the United States. Poster presented at the National HIV Prevention Conference; August 2009.

Bradley-Kennedy C, Wolowacz SE, Roskell NS. Cost-effectiveness of dabigatran etexilate in Canada for the primary prevention of venous thromboembolism in patients undergoing total knee or total hip replacement surgery. Poster presented at the International Society on Thrombosis and Haemostasis 22nd International Congress; July 11, 2009. Boston, MA.

Hoerger TJ, Zhang P, Segel JE, Gregg EW, Narayan K, Hicks KA. Improvements in risk factor control among persons with diabetes in the United States: evidence and implications for remaining life expectancy. Presented at the 7th World Conference on Health Economics; July 2009. Previously presented at the American Diabetes Association 69th Scientific Sessions.

Bischof M, Brogan AJ, Talbird SE, Cavassini M, Bernasconi E, Furrer H. Cost-effectiveness of the first-line antiretroviral backbone therapies in combination with efavirenz in HIV-infected patients in Switzerland. Poster presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 2009. Cape Town, South Africa.

Hoerger TJ, Zhang P, Segel JE, Gregg E, Narayan K, Hicks KA. Improvements in risk factor control among persons with diabetes in the United States: evidence and implications for remaining life expectancy. Presented at the American Diabetes Association 69th Scientific Sessions; June 2009.

Klok R, Strutton DR, Postma M, Earnshaw SR, Farkouh RA. Public health and economic impact of 13-valent pneumococcal conjugate vaccination in the Netherlands. Poster presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases; June 2009.

Earnshaw SR, Wilson M, Mauskopf J, Joshi AV. Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges. Value Health. 2009 Jun 1;12(4):507-20.

Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy. 2009 Jun 1;7(2):91-108.

Strutton DR, Kuchenbecker U, Earnshaw SR, Farkouh RA. Impact of 13-valent pneumococcal conjugate vaccination on costs and outcomes in Germany and the United States. Poster presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases; June 2009.

Stoykova B, Strutton DR, Earnshaw SR, Farkouh RA. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination relative to 7-valent pneumococcal conjugate vaccination in the United Kingdom (UK). Poster presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases; June 2009. Brussels, Belgium.

Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson PA, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150 MG for the prevention of venous thromboembolism in elderly patients undergoing total hip or knee arthroplasty. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 16, 2009. Orlando, FL.

Wolowacz S, Roskell N, Plumb J, Clemens A, Robinson P, Dolan G, Brenkel I. Cost-effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty that have moderate impairment of renal function. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 1, 2009. [abstract] Value Health. 2009 May; 12(3):A151.

Soorapanth S, Brogan AJ, Mrus J, Smets E. Comparative cost-efficacy analysis of darunavir/r for first-line treatment of HIV infection in the US. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; May 2009. [abstract] Value Health. 12(3):A112.

Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson P, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150 MG for the prevention of venous thromboembolism in patients aged over 75 years undergoing total hip or knee arthroplasty. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 14, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A151.

Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson P, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty with moderate impairment of renal function. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 15, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A151.